+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Ketoacidosis - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • February 2021
  • Region: Global
  • DelveInsight
  • ID: 5240434
UP TO OFF until Dec 31st 2023
This “Diabetic Ketoacidosis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Ketoacidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Diabetic Ketoacidosis Understanding

Diabetic Ketoacidosis: Overview

Diabetic ketoacidosis (DKA), is a buildup of acids in the blood. It can happen when the blood sugar levels remain high for a long time. It occurs when absolute or relative insulin deficiency inhibits the ability of glucose to enter cells for utilization as metabolic fuel, and as a result the liver rapidly breaks down fat into ketones to employ as a source of fuel. The overproduction of ketones causes them to accumulate in the blood and urine and turn the blood acidic. The treatment for DKA usually involves a combination of approaches to normalize blood sugar and insulin levels. The therapies involved in the treatment of diabetic ketoacidosis are: fluid replacement therapy, insulin therapy, and electrolyte replacement.

"Diabetic ketoacidosis- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic ketoacidosis pipeline landscape is provided which includes the disease overview and Diabetic ketoacidosis treatment guidelines. The assessment part of the report embraces, in depth Diabetic ketoacidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic ketoacidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Ketoacidosis R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Ketoacidosis.

Diabetic Ketoacidosis Emerging Drugs Chapters

This segment of the Diabetic Ketoacidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Ketoacidosis Emerging Drugs

  • PMZ 2123: Pharmazz
PMZ-2123 prevents the development of neurological complications in diabetic ketoacidosis patients. Intravenous administration of PMZ-2123 prevents the development of cerebral edema in patients of diabetic ketoacidosis. Efficacy has been demonstrated in animal models of diabetic ketoacidosis.

Diabetic Ketoacidosis: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Ketoacidosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Ketoacidosis

There are approx. 3+ key companies which are developing the therapies for Diabetic Ketoacidosis. The companies which have their Diabetic Ketoacidosis drug candidates in the mid to advanced stage, i.e. Phase I include, Pharmzz and others.

The report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Diabetic Ketoacidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Ketoacidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Ketoacidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Ketoacidosis drugs.

Diabetic Ketoacidosis Report Insights

  • Diabetic Ketoacidosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Diabetic Ketoacidosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetic Ketoacidosis drugs?
  • How many Diabetic Ketoacidosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Ketoacidosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Ketoacidosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Ketoacidosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Pharmzz

Key Products

  • PMZ 2123

Table of Contents


Executive Summary

Diabetic Ketoacidosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Diabetic Ketoacidosis - Analytical Perspective

In-depth Commercial Assessment
  • Diabetic Ketoacidosis companies' collaborations, Licensing, Acquisition - Deal Value Trends

Diabetic Ketoacidosis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Early Stage Products (Phase I)
  • Comparative Analysis

PMZ 2123: Pharmazz
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Diabetic Ketoacidosis Key Companies

Diabetic Ketoacidosis Key Products

Diabetic Ketoacidosis - Unmet Needs

Diabetic Ketoacidosis - Market Drivers and Barriers

Diabetic Ketoacidosis - Future Perspectives and Conclusion

Diabetic Ketoacidosis Analyst Views

Diabetic Ketoacidosis Key Companies

AppendixList of Tables
Table 1 Total Products for Diabetic Ketoacidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Diabetic Ketoacidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pharmzz